Abstracts Archive - Page 2375 of 2425 - ACR Meeting Abstracts

Abstract Number: 700 • 2012 ACR/ARHP Annual Meeting
Clinical Correlation of Flow-Mediated Endothelium-Dependent Vasodilatation in Systemic Sclerosis
Takehiro Takahashi¹, Yoshihide Asano¹, Eisuke Amiya², Masaru Hatano³, Atsuko Ozeki², Aya Watanabe², Shuichi Kawarasaki², Tomoko Nakao², Zenshiro Tamaki⁴, Takashi Taniguchi⁵, Yohei Ichimura⁵, Tetsuo Toyama¹, Masafumi Watanabe⁶, Yasunobu Hirata², Ryozo Nagai³ and Shinichi Sato⁷, ¹Department of Dermatology, University of Tokyo Graduate School of Medicine, Tokyo, Japan, ²Department of Cardiovascular Medicine, University of Tokyo Graduate School of Medicine, Tokyo, Japan, ³Cardiovascular Medicine, University of Tokyo Graduate School of Medicine, Tokyo, Japan, ⁴Medicine, Rheumatology, Department of Dermatology, University of Tokyo Graduate School of Medicine, Tokyo, Japan, ⁵Dermatology, University of Tokyo Graduate School of Medicine, Tokyo, Japan, ⁶Cardiovascular Medicine, Department of Cardiovascular Medicine, University of Tokyo Graduate School of Medicine, Tokyo, Japan, ⁷Department of Dermatology, Faculty of Medicine, University of Tokyo, Tokyo, Japan
Background/Purpose: Systemic sclerosis (SSc) is a multisystem autoimmune disease characterized by initial vascular injuries and resultant fibrosis of skin and certain internal organs. Evidence has…
Abstract Number: 701 • 2012 ACR/ARHP Annual Meeting
Vascular Differences Associated to Genetic Polymorphisms of Endothelial Nitric Oxide Synthase in Mexican Patients with Systemic Sclerosis. A Preliminary Report
Maria Pilar Cruz-Dominguez¹, Maria Angeles Martinez-Godinez², Angel Miliar-Garcia², Daniel Hector Montes-Cortes³, Olga Vera-Lastra⁴, Luis J. Jara-Quezada⁵ and Anabel Reyes-Salazar⁶, ¹Division of Research, Hospital de Especialidades Centro Medico Nacional La Raza., Mexico, DF, Mexico, ²Postgraduate Studies and Research Section, Escuela Superior de Medicina. IPN,, Mexico, D.F., Mexico, ³Investigación, Hospital General CMN La Raza, IMSS, Mexico DF, Mexico, ⁴Internal Medicine, MD, Mexico City, Mexico, ⁵Direction of Education and Research, Hospital de Especialidades Centro Médico La Raza, IMSS, Mexico City, Mexico, ⁶Angiology, Hospital de especialidades Centro Medico National “La Raza”, IMSS, Mexico, D.F., Mexico
Background/Purpose: Vascular dysfunction usually is observed before clinically detectable fibrosis of systemic sclerosis (SSc). The eNOS catalyses the synthesis of nitric oxide (NO), which maintains…
Abstract Number: 702 • 2012 ACR/ARHP Annual Meeting
Arterial Stiffness Is Increased in Systemic Sclerosis: A Cross-Sectional Comparison with Matched Controls
Gene-Siew Ngian¹, Joanne Sahhar², Ian Wicks³ and Sharon Van Doornum⁴, ¹Department of Medicine (RMH/WH), The University of Melbourne, Parkville, Australia, ²Rheumatology Unit, Monash Medical Centre, Clayton, Australia, ³Rheumatology Unit, Royal Melbourne Hospital, Melbourne, Australia, ⁴Department of Medicine (RMH/WH), The University of Melbourne, The Royal Melbourne Hospital, Melbourne, Australia
Background/Purpose: Atherosclerosis may be increased in systemic sclerosis (SSc)1. Increased arterial stiffness is a predictor of cardiovascular and all-cause mortality across a wide range of…
Abstract Number: 703 • 2012 ACR/ARHP Annual Meeting
Vascular Ischemic Events in Systemic Sclerosis – A Cross-Sectional Comparision with Population-based Controls
Annica Nordin¹, Kerstin Jensen-Urstad², Lena Björnådal³ and Elisabet Svenungsson³, ¹Rheumatology Unit, Department of Medicine, Karolinska University Hospital, Karolinska Institute, Stockholm, Sweden, ²Department of Clinical Physiology, Södersjukhuset, Karolinska Institutet, Stockholm, Sweden, ³Department of Medicine, Rheumatology Unit, Karolinska Institutet, Stockholm, Sweden
Background/Purpose: To investigate the occurrence of ischemic vascular events and subclinical atherosclerosis in patients with systemic sclerosis (SSc) and matched population controls. Methods: 111 SSc…
Abstract Number: 704 • 2012 ACR/ARHP Annual Meeting
Decreased Number of Endothelial Progenitor Cells in Systemic Sclerosis Patients with Early Disease
Fernando V. Andrigueti, Maria I. Arismendi, Pâmela C.C. Ebbing and Cristiane Kayser, Rheumatology Division, Universidade Federal de São Paulo, São Paulo, Brazil
Background/Purpose: Microangiopathy and endothelial dysfunction are present in early phases of Systemic sclerosis (SSc), resulting in decreased blood flow and tissue ischemia. Several mechanisms including…
Abstract Number: 705 • 2012 ACR/ARHP Annual Meeting
Adipose Derived Stem Cells As an Alternative Source of Cellular Repair for Vascular Dysfunction in Systemic Sclerosis
Nevin Hammam¹ and Hazem Orabi², ¹Rheumatology Department, Assiut University, Assiut, Egypt, ²University of California, San Francisco,, Knuppe Molecular Laboratory, San Francisco, CA
Background/Purpose: Systemic sclerosis (SSc) is autoimmune disease characterized by autoimmunity, diffuse fibrosis in the skin and internal organs, and vasculopathy in moderate size arteries and…
Abstract Number: 706 • 2012 ACR/ARHP Annual Meeting
Excess Mortality From Atherosclerotic Cardiovascular Disease in Systemic Sclerosis Compared to Lupus and Rheumatoid Arthritis
Amish J. Dave¹, Bharathi Lingala², David Fiorentino³, Eswar Krishnan⁴ and Lorinda Chung⁵, ¹Stanford University, Stanford, CA, ²Dermatology, Stanford University, Redwood City, CA, ³Dermatology, Stanford University School of Medicine, Redwood City, CA, ⁴Medicine, Standford University, Palo Alto, CA, ⁵Rheumatology, Stanford Univ Medical Center, Palo Alto, CA
Background/Purpose: Patients with autoimmune connective tissue diseases (CTD), including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA), are at increased risk for atherosclerotic cardiovascular disease…
Abstract Number: 707 • 2012 ACR/ARHP Annual Meeting
Risk of Cancer in Systemic Sclerosis: Meta-Analysis of Population-Based Cohort Studies
Akira Onishi¹, Daisuke Sugiyama², Akio Morinobu³ and Shunichi Kumagai⁴, ¹Rheumaology and Clinical Immunology, Kobe University Graduate School of Medicine, Kobe, Japan, ²Department of Preventive Medicine and Public Health, School of Medicine, Keio University, Tokyo, Japan, ³Department of Clinical Pathology and Immunology, Kobe University Graduate School of Medicine, Kobe, Japan, ⁴Center of Rheumatic Diseases, Shinko Hospital, Kobe, Japan
Background/Purpose: The risk of cancer compared with general population has been elevated in several connective tissue diseases. However, the standardized incidence ratios (SIRs) for overall…
Abstract Number: 708 • 2012 ACR/ARHP Annual Meeting
Histological Features of Localized Scleroderma‘en Coup De Sabre‘: A Study of 16 Cases
Takashi Taniguchi, Yoshihide Asano, Zenshiro Tamaki, Kaname Akamata, Naohiko Aozasa, Shinji Noda, Takehiro Takahashi, Yohei Ichimura, Tetsuo Toyama, Miki Sugita, Hayakazu Sumida, Yoshihiro Kuwano, Miki Miyazaki, Koichi Yanaba and Shinichi Sato, Dermatology, University of Tokyo Graduate School of Medicine, Tokyo, Japan
Background/Purpose: Scleroderma is a chronic disease of unknown etiology characterized by skin fibrosis and is divided into two clinical entities: localized scleroderma and systemic sclerosis.…
Abstract Number: 709 • 2012 ACR/ARHP Annual Meeting
Fingertip Skin Hardness in Limited Scleroderma: Durometry versus Manual Assessment
Thomas Osborn¹, Eric L. Matteson¹, Floranne Ernste², Cynthia S. Crowson³, Deana D. Hoganson⁴ and Irene Z. Whitt⁵, ¹Rheumatology, Mayo Clinic, Rochester, MN, ²Division of Rheumatology, Mayo Clinic Rochester, Rochester, MN, ³Department of Health Sciences Research, Mayo Clinic, Rochester, MN, ⁴Rheumatology, Mercy Arthritis and Osteoporosis Center, Urbandale, IA, ⁵NIH/NIEHS/Environmental Autoimmunity Group, Bethesda, MD
Background/Purpose: Skin manifestations of scleroderma involve the digits in nearly all patients. Assessment of change at the level of digital skin involvement is difficult. The Modified…
Abstract Number: 710 • 2012 ACR/ARHP Annual Meeting
Optical Density Measure of the Papillary Dermis Discriminates As Abnormal Clinically Uninvolved Skin in Systemic Sclerosis and Correlates with Severity of Skin Thickness
Giuseppina Abignano¹, Sibel Z. Aydin², Concepcion Castillo-Gallego³, Daniel Woods⁴, Adam Meekings⁵, Dennis McGonagle⁶, Paul Emery⁷ and Francesco Del Galdo⁸, ¹Chapel Allerton Hospital Leeds Insitute of Molecular medicine, Division of Rheumatic and Musculoskeletal Disease, University of Leeds, Leeds Institute of Molecular Medicine and LMBRU, Leeds, United Kingdom, ²Unit of Rheumatology, Medeniyet University, Goztepe Training and Research Hospital, Istanbul, Turkey, ³Rheumatology, Hospital La Paz - IdiPaz, Madrid, Spain, ⁴Michelson Diagnostics Ltd, Kent, United Kingdom, ⁵Michelson Diagnostics Ltd, Kent, United Kingdom, Kent, United Kingdom, ⁶Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ⁷Division of Rheumatic and Musculoskeletal Disease, University of Leeds, Leeds Institute of Molecular Medicine and LMBRU, Leeds, United Kingdom, ⁸Musculoskeletal Diseases, University of Leeds, Leeds Institute of Molecular Medicine and LMBRU, Leeds, United Kingdom
Background/Purpose: Skin involvement in systemic sclerosis (SSc) is often primary outcome in clinical trials and its severity inversely correlates with prognosis. Nevertheless, an objective quantitative…
Abstract Number: 671 • 2012 ACR/ARHP Annual Meeting
Differences in the SLE Clinical Phenotype by Age of Diagnosis
T. Clark Powell¹, Elizabeth E. Brown on behalf of PROFILE², Gerald McGwin Jr.³, Luis M. Vila⁴, Yesenia C. Santiago-Casas⁴, Michelle Petri⁵, Rosalind Ramsey-Goldman⁶, John D. Reveille⁷, Sergio Duran⁸, Sergio M.A. Toloza⁹, Robin L. Brey¹⁰, Agustin Escalante¹¹, Randy Q. Cron¹², Robert P. Kimberly on behalf of PROFILE investigators¹³ and Graciela S. Alarcon¹⁴, ¹Medicine, University of Alabama at Birmingham, Birmingham, AL, ²University of Alabama at Birmingham, Birmingham, AL, ³Epidemiology, University of Alabama at Birmingham, Birmingham, AL, ⁴Department of Medicine, Division of Rheumatology, University of Puerto Rico Medical Sciences Campus, San Juan, PR, ⁵Johns Hopkins University School of Medicine, Baltimore, MD, ⁶Medicine/Rheumatology, Northwestern University Feinberg School of Medicine, Chicago, IL, ⁷Internal Medicine/Rheumatology, Univ of Texas Health Science Center at Houston, Houston, TX, ⁸UIECD, Guadalajara, Mexico, Guadalajara, Mexico, ⁹Medicine, Hospital San Juan Bautista, Catamarca, Argentina, ¹⁰Medicine/Neurology, UTHSCSA, San Antonio, TX, ¹¹Dept. of Medicine-Rheumatology, University of Texas Health Science Center at San Antonio, San Antonio, TX, ¹²Pediatric Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ¹³Clinical Immun & Rheumatology, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, ¹⁴Medicine, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Systemic lupus erythematosus (SLE) is a prototypic autoimmune disease that is characterized by the presence of antinuclear autoantibodies, complement activation and the formation and…
Abstract Number: 672 • 2012 ACR/ARHP Annual Meeting
Immune Complexes and Autoantibodies to Oxidized Lipids in Systemic Lupus Erythematosus
Yujin Ye¹, Tianfu Wu¹ and Chandra Mohan², ¹Division of Rheumatology/Internal Medicine, University of Texas, Southwestern Medical Center at Dallas, Dallas, TX, ²University of Houston, Houston, TX
Background/Purpose: SLE is a chronic autoimmune inflammatory disease. Increasing evidence suggest that excess production of reactive oxygen species (ROS) may cause oxidative stress and favor…
Abstract Number: 673 • 2012 ACR/ARHP Annual Meeting
Altered Soluble Mediators in Individuals with Incomplete Lupus (ILE) in the Lupus Autoimmunity in Relatives (LAUREL) Study
Melissa E. Munroe¹, Jill M. Norris², Joel M. Guthridge³, Diane L. Kamen⁴, Kathy Moser Sivils⁵, Timothy B. Niewold⁶, Gary S. Gilkeson⁷, Michael H. Weisman⁸, Mariko L. Ishimori⁸, Daniel J. Wallace⁹, David R. Karp¹⁰, John B. Harley¹¹ and Judith A. James¹², ¹Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Epidemiology, Colorado School of Public Health, Aurora, CO, ³Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁴Department of Medicine, Arthritis & Clinical Immunology Program, Oklahoma Medical Research Foundation, Charleston, SC, ⁵Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁶Section of Rheumatology and Gwen Knapp Center for Lupus and Immunology Research, University of Chicago, Chicago, IL, ⁷Department of Medicine, Division of Rheumatology, Medical University of South Carolina, Charleston, SC, ⁸Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, ⁹Cedars-Sinai Medical Center, Los Angeles, CA, ¹⁰Rheumatic Diseases Division, UT Southwestern Medical Center, Dallas, TX, ¹¹Division of Rheumatology and The Center for Autoimmune Genomics & Etiology, University of Cincinnati, Cincinnati Children's Hospital Medical Center; US Department of Veterans Affairs Medical Center, Cincinnati, OH, ¹²Oklahoma Medical Research Foundation; University of Oklahoma Health Sciences Center, Oklahoma City, OK
Background/Purpose: SLE is a complex autoimmune disease marked by autoantibody production and immune dysregulation. Identification of at-risk populations is essential to minimize morbidity and mortality…
Abstract Number: 674 • 2012 ACR/ARHP Annual Meeting
Altered Response to B Cell Receptor (BCR) Crosslinking in SLE: Correlation with Genetic Risk Variants Predicted to Impact BCR Signaling
Nan-Hua Chang¹, Timothy Li², Paul R. Fortin³, Dafna D. Gladman⁴, Carolina Landolt-Marticorena⁵, Jorge Sanchez-Guerrero⁶, Murray B. Urowitz⁷ and Joan E. Wither⁸, ¹Genetics and Development, Toronto Western Research Institute, Toronto Western Hospital, Toronto, ON, Canada, ²Genetics and developmental biology, Toronto Western Hospital, Toronto, ON, Canada, ³University of Laval, Quebec, QC, Canada, ⁴Centre for Prognosis Studies in The Rheumatic Diseases, Toronto Western Research Institute, University of Toronto, University Health Network, Toronto, ON, Canada, ⁵Rheumatology, University Health Network, University of Toronto, Toronto, ON, Canada, ⁶UHN Toronto Western Hospital, Toronto, ON, Canada, ⁷Division of Rheumatology, University Health Network, University of Toronto, Toronto, ON, Canada, ⁸1E420/Div of Rheumatology, Toronto Western Research Institute, University of Toronto, University Health Network, Toronto, ON, Canada
Background/Purpose: Altered B cell signaling has been proposed to play an important role in susceptibility to SLE. In mice, genetic manipulations or polymorphisms that attenuate…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].